Skip to main content

Absence of Signs or Symptoms

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
Biospecimen CollectionN/A
Kite Pharma
Kite PharmaCA - El Segundo
1 program
Biospecimen CollectionN/A1 trial
Active Trials
NCT02928510Terminated1Est. Jun 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Kite PharmaBiospecimen Collection

Clinical Trials (1)

Total enrollment: 1 patients across 1 trials

NCT02928510Kite PharmaBiospecimen Collection

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

Start: Feb 2016Est. completion: Jun 20181 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.